MyMyelomaTeam

What a thoughtful and thorough set of questions — it's clear how much care and research you're putting into supporting your husband through this. Let's work through what's known.

On remission depth and duration with teclistamab

The older "each remission gets shorter" pattern was based on older treatment classes. Newer Show Full Answer

What a thoughtful and thorough set of questions — it's clear how much care and research you're putting into supporting your husband through this. Let's work through what's known.

On remission depth and duration with teclistamab

The older "each remission gets shorter" pattern was based on older treatment classes. Newer BCMA-targeted therapies like teclistamab work through a completely different mechanism, so that historical pattern may not apply in the same way.

Clinical trial data for teclistamab shows:

- An overall response rate of around 61.8%
- At nine months, about 66.5% of responders were still in response
- People on teclistamab showed better progression-free survival and overall survival compared to those on standard therapies

So achieving a deeper response (CR vs. VGPR) with teclistamab is genuinely meaningful — deeper responses are generally associated with longer remissions, regardless of what came before. On teclistamab combined with other treatments

There is also emerging data on combining teclistamab with daratumumab (even in CD38-refractory settings, combinations are being studied). In one study, the teclistamab plus daratumumab combination showed:

- An 83% lower risk of disease progression or death
- An 83% three-year progression-free survival rate
- An 89% overall response rate at three years

This may be relevant for future conversations with his care team about what comes next, if needed. On CRS and side effects during step-up dosing

Cytokine release syndrome (CRS) is one of the more commonly watched-for side effects with teclistamab, especially during step-up dosing. Symptoms can include:

- Fever and chills
- Breathing difficulties
- Fatigue
- Headache
- Nausea

Given your husband's existing chronic pain and other health issues, it can genuinely be hard to separate what's treatment-related versus myeloma-related versus pre-existing. Keeping a simple daily symptom log — noting timing, severity, and any new changes — can be a helpful tool to share with his team.

His medical team will be monitoring him closely during this step-up phase, which is exactly the right time to flag anything that feels new or different, even if it seems minor. Hearing from others with teclistamab experience

Many MyMyelomaTeam members have shared their teclistamab journeys — including experiences with CRS timing, fatigue, infections, and what came next after teclistamab. Reading through those conversations may give you a much more personal and practical picture of what day-to-day life on this treatment can look like.

Wishing your husband a smooth third dose on Monday and a strong response ahead. 💙

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

BiTE Therapy for Myeloma: How Bispecific Antibodies Work

FDA-Approved Drug Combo Lowers Myeloma Progression Risk by 83%